[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Hopkins et al., 2004 - Google Patents

Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.

Hopkins et al., 2004

Document ID
2182127007553601337
Author
Hopkins A
Ren J
Milton J
Hazen R
Chan J
Stuart D
Stammers D
Publication year
Publication venue
Journal of medicinal chemistry

External Links

Snippet

We have used a structure-based approach to design a novel series of non-nucleoside inhibitors of HIV-1 RT (NNRTIs). Detailed analysis of a wide range of crystal structures of HIV- 1 RT− NNRTI complexes together with data on drug resistance mutations has identified …
Continue reading at pubs.acs.org (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions

Similar Documents

Publication Publication Date Title
Hopkins et al. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.
Wells et al. Development of a potent and selective chemical probe for the pleiotropic kinase CK2
Kang et al. Structure-based bioisosterism yields HIV-1 NNRTIs with improved drug-resistance profiles and favorable pharmacokinetic properties
Kang et al. Identification of dihydrofuro [3, 4-d] pyrimidine derivatives as novel HIV-1 non-nucleoside reverse transcriptase inhibitors with promising antiviral activities and desirable physicochemical properties
Ragno et al. Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2, 6-difluorophenyl) alkyl]-3, 4-dihydro-5-alkylpyrimidin-4 (3 H)-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C variant
Himmel et al. HIV-1 reverse transcriptase structure with RNase H inhibitor dihydroxy benzoyl naphthyl hydrazone bound at a novel site
Bauman et al. Detecting allosteric sites of HIV-1 reverse transcriptase by X-ray crystallographic fragment screening
Scapin et al. The structural basis for the selectivity of benzotriazole inhibitors of PTP1B
Dvir et al. 3D structure of Torpedo californica acetylcholinesterase complexed with huprine X at 2.1 Å resolution: kinetic and molecular dynamic correlates
Fick et al. Sulfur–oxygen chalcogen bonding mediates adomet recognition in the lysine methyltransferase SET7/9
Singh et al. Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases
Martin et al. Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains
Hou et al. Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with amprenavir and two amprenavir-related inhibitors: mechanism for binding and drug resistance
Nguyen et al. Deoxyuridine triphosphate nucleotidohydrolase as a potential antiparasitic drug target
Leonidas et al. Crystal Structures of Ribonuclease A Complexes with 5 ‘-Diphosphoadenosine 3 ‘-Phosphate and 5 ‘-Diphosphoadenosine 2 ‘-Phosphate at 1.7 Å Resolution
Keough et al. Aza-acyclic nucleoside phosphonates containing a second phosphonate group as inhibitors of the human, Plasmodium falciparum and vivax 6-oxopurine phosphoribosyltransferases and their prodrugs as antimalarial agents
Bosch et al. Using fragment cocktail crystallography to assist inhibitor design of Trypanosoma brucei nucleoside 2-deoxyribosyltransferase
Dayam et al. Diketo acid pharmacophore. 2. Discovery of structurally diverse inhibitors of HIV-1 integrase
Coumar et al. Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification
Ren et al. Relationship of potency and resilience to drug resistant mutations for GW420867X revealed by crystal structures of inhibitor complexes for wild-type, Leu100Ile, Lys101Glu, and Tyr188Cys mutant HIV-1 reverse transcriptases
Piscitelli et al. Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus
Rodríguez-Barrios et al. The molecular basis of resilience to the effect of the Lys103Asn mutation in non-nucleoside HIV-1 reverse transcriptase inhibitors studied by targeted molecular dynamics simulations
Postigo et al. Discovery of new inhibitors of Schistosoma mansoni PNP by pharmacophore-based virtual screening
Mugnaini et al. Dihydro-alkylthio-benzyl-oxopyrimidines as inhibitors of reverse transcriptase: synthesis and rationalization of the biological data on both wild-type enzyme and relevant clinical mutants
Qin et al. Diarylaniline derivatives as a distinct class of HIV-1 non-nucleoside reverse transcriptase inhibitors